Global Connected Drug Delivery Devices Market By Product (Connected Sensors and Integrated Connected Devices), By Technology (Bluetooth, Near-field communication (NFC), and Other Technologies), By Application (Diabetes, Respiratory, Cardiovascular, Anaphylaxis and Others); By Route of Administration (Injectable and Inhalational); By End-User (Hospitals and Home Care); By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

According to a recent report by Market.us, the Global Connected Drug Delivery Devices Market size is expected to be worth around USD 2,980.9 Million by 2032 from USD 349.2 Million in 2022, growing at a CAGR of 24.6% during the forecast period from 2023 to 2032.

The connected drug delivery devices are the medical devices incorporating digital connectivity and communication capabilities that enable monitoring, tracking, and controlling the administration of medicine. In addition, these devices power the technology that improves treatment outcomes, enhances patient adherence, and provides healthcare professionals with precise data for personalized care. The growth of the global connected drug delivery devices can be attributed to the increasing prevalence of chronic diseases, advancements in digital health technologies, and the need for personalized medicine.

Moreover, the connected drug delivery devices offer the features such as real-time monitoring, dose tracking, reminders, and data sharing with healthcare providers, thereby improving medication adherence and patient engagement. As a result, it is expected to boost the market growth.

Key Takeaways

• Connected drug delivery devices are the medical devices that utilize digital technologies with the intention to effectively monitor the efficacy of the delivered medical treatment along with health of the patient.
• Among products, the integrated connected devices segment was responsible for highest revenue generation.
• Based on technology Bluetooth segment claimed the largest market share, amounting to 47%
• By claiming a 31% market share, the diabetes segment continues to be the highest contributor to the connected drug delivery devices market.
• The injectable route of administration segment has offered the most contribution to the  connected drug delivery devices market.
• As far as end users are concerned, home care segment is expected to expand with an unmatched CAGR during the forecast period.
• Region-wise, North America continued to dominate the connected drug delivery devices market in 2022, with a market share of 35%.
• Asia-Pacific is predicted to experience a dynamic growth with the highest CAGR during 2023-2032.

Driving Factors

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases the such as asthma, diabetes, and cardiovascular diseases mainly drives the growth of the global connected drug delivery devices market. This has created a need for convenient and effective drug delivery solutions. The connected drug delivery devices offer the features such as real-time monitoring, dose tracking, reminders, and data sharing with healthcare providers, thereby improving medication adherence and patient engagement, thereby driving the market growth.

Technological advancement surges the market growth

The rapid advancements in technology, such as wireless connectivity, sensor technology, and miniaturization, have allowed the development of connected drug delivery devices which offer improved accuracy, enhanced patient engagement, and real-time monitoring, leading to better treatment outcomes. As a result, technological advancement will likely fuel market growth during the forecast period.

Restraining Factors

Data Privacy and Security Concerns

Connected drug delivery devices produce and transfer sensitive patient data, such as treatment data and personal health information. Therefore, to gain the trust of patients, healthcare providers, and regulatory bodies, ensuring robust data privacy and security is crucial to taking certain measures. Any mishandling or breach of the patient’s sensitive data can challenge the adoption and acceptance of these devices, restricting market growth.

Product Analysis

Integrated connected devices accounted for the highest revenue share in 2022.

Based on product, the global connected drug delivery devices market is divided into connected sensors and integrated devices. Among these, the integrated connected devices segment dominated the global connected drug delivery devices market in 2022. Integrated drug delivery devices offer several benefits, including improved medication adherence, enhanced patient monitoring, and remote healthcare management. Moreover, these connected devices can provide patient reminders or alerts for medication schedules, allow real-time data tracking, and share data with healthcare providers.

Technology Analysis

Bluetooth segment dominated the global market with the largest share of 47% in 2022.

The global connected drug delivery devices market is segmented based on technology into Bluetooth, near-field communication (NFC), and other technologies. Among these, the Bluetooth segment accounted for the highest revenue share of 47% in 2022. The segment growth is propelled by the technology that offers wireless connectivity and data transfer capabilities for drug delivery devices. In addition, Bluetooth-enabled devices can communicate with tablets, smartphones, and other healthcare systems, allowing for remote monitoring, seamless data transmission, and enhanced patient engagement.

Application Analysis

The diabetes segment continues to contribute the most.

The market is further segmented into five definite segments, namely, diabetes, respiratory, cardiovascular, anaphylaxis, and others. Diabetes is the dominating segment in the connected drug delivery devices market, with a market share of 31%. Diabetes is followed by respiratory and cardiovascular segments. Other applications segment generates the least revenue.

Route of Administration Analysis

Injectable mode is most commonly used in 2022.

Such connected rug delivery devices can be administered by two methods. The most common method is injecting patients with the drug delivery devices. As a result, this particular segment remains the largest contributor. Alternatively, the inhalational drug delivery devices generate comparatively less revenue.

End-User Analysis

The home care segment is projected to dominate the global market during the forecast period

Based on end-user, the global connected drug delivery devices market is divided into hospitals and home care. The home care segment is projected to hold the largest revenue share during the forecast period. The rising adoption of connected drug delivery devices is a key driver behind the growth of this segment. In addition, the need to provide better patient experience and the rising prevalence of asthma and COPD are also anticipated to surge the market growth.  Moreover, home care is often more cost-effective than hospital care. The connected drug delivery devices let the patients receive their treatment at home while being in contact with healthcare providers. This reduces the need for frequent hospital visits, positively driving the market growth.

Key Market Segments

By Product

• Connected Sensors
• Integrated Connected Devices

By Technology

• Bluetooth
• Near-field communication (NFC)
• Other Technologies

By Application

• Diabetes
• Respiratory
• Cardiovascular
• Anaphylaxis
• Other Applications

By Route of Administration

• Injectable
• Inhalational

By End-User

• Hospitals
• Home Care

Growth Opportunity

Expansion into emerging markets, personalized medicine, and targeted therapy to offer significant growth opportunities

Due to the improvement of healthcare infrastructure and better access to healthcare in emerging markets, there is a significant opportunity for the adoption of connected drug delivery devices. These devices enhance disease management in regions with limited healthcare resources. Moreover, the connected drug delivery devices allow personalized medicine by providing real-time data on how the patient responds to the medication. This data helps healthcare providers optimize treatment plans, tailor the therapies to individual patients, and adjust dosages, leading to better treatment outcomes.

Latest Trends

Artificial intelligence (AI), machine learning (ML), wearable, and implantable technologies to propel the market growth

Artificial intelligence and Machine Learning algorithms are increasingly being applied to connected drug delivery devices to analyze large volumes of data. In addition, these technologies can help to personalize treatment plans, optimize dosing regimens, and predict patient response to medication. AI-powered devices adapt the treatment strategies over time by learning from patient’s data. Moreover, integrating connected drug delivery devices with wearable and implantable technologies has gained huge popularity. Implantable devices reduce the need for frequent administration, providing long-term medication delivery. Wearable devices like smartwatches can monitor vital signs, deliver personalized alerts, and track medication usage. These are the major factors propelling the market growth.

Regional Analysis

North America dominated the global connected drug delivery devices market with the highest revenue share of 35% in 2022

Based on region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the highest revenue share of 35% among these regions in 2022. This regional growth can be highly attributed to the region’s high per capita healthcare spending. In addition, the growing adoption of remote monitoring for medication adherence, the presence of the most prominent players, and the rapid adoption of technology are also driving the regional market growth exponentially.

Asia Pacific is projected to expand at the highest CAGR during the forecast period

The market for connected drug delivery devices in Asia Pacific is growing as a result of the growing number of companies and initiatives deployed by them in this region. Moreover, the market growth of this region is also fueled due to rising prevalence of chronic diseases and the availability of a huge patient population base.

Key Regions

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

Emerging key players in the global connected drug delivery devices market are now focused on implementing strategies such as partnerships, collaborations, mergers & acquisitions, new product launches, and competitive pricing.  Moreover, they are concentrating on geographic expansion to increase their foreign presence.  This forms the competitive landscape in the global market and drives further market growth. Medium to small companies are focused on precise solutions which cater to the market’s customer requirements, e.g., software for connected devices, sensor manufacturing, etc. However, large companies are widely traded and have diverse portfolios with robust research & development, distribution, and sales capabilities.

Top Key Players

Listed below are the key players operating in the connected drug delivery market.

• Medtronic plc
• Johnson & Johnson Services Inc.
• Propeller Health (ResMed Inc.)
• BIOCORP
• Adherium Limited
• West Pharmaceutical Services Inc
• Becton Dickinson and Company
• Ypsomed AG
• Tandem Diabetes Care Inc.
• Other Key Players

Recent Developments

• May 2022: a division of Jabil Inc (Jabil Healthcare) announced the launch of a reusable drug delivery device, a Qfinity autoinjector platform, in the US for self-administration of subcutaneous drugs. This product is also available in connected options.
• July 2023: Tandem Mobi insulin pump received US FDA clearance. The pump is world’s smallest insulin delivery system and can be remote controlled with the help of a mobile app. It comes with multiple wear alternatives and is equipped with detachable infusion sets.

Report Scope